Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Orchestra BioMed Holdings, Inc. - Ordinary Shares (NQ: OBIO )

4.020 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1
Open 4.020
Bid (Size) 1.620 (1)
Ask (Size) 6.430 (2)
Prev. Close 4.020
Today's Range 4.020 - 4.020
52wk Range 3.750 - 8.870
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Orchestra BioMed to Present at Upcoming Investor Conferences
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire

Performance

YTD
-25.28%
-25.28%
1 Month
-27.96%
-27.96%
3 Month
-24.86%
-24.86%
6 Month
-29.35%
-29.35%
1 Year
-26.10%
-26.10%

More News

Read More
Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
This Kopin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Orchestra BioMed Announces AVIM Therapy Program Presentations at ICI Meeting
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed to Participate in Jefferies London Healthcare Conference
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
OBIO Stock Earnings: Orchestra BioMed Hldgs Misses EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Announces Appointment of Cardiovascular Device Industry Expert John Mack to Board of Directors
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Precision Neuroscience Expands Executive Team as Brain–Computer Interface Industry Rapidly Advances
From Precision Neuroscience
Via GlobeNewswire
Orchestra BioMed Announces Further Details on In-Person R&D Day in New York Featuring Key Opinion Leaders to Discuss AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed to Participate in Jefferies Global Healthcare Conference
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
OBIO Stock Earnings: Orchestra BioMed Hldgs Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
OBIO Stock Earnings: Orchestra BioMed Hldgs Beats EPS, Misses Revenue for Q4 2023
Via InvestorPlace
Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.